Retina

An end-of-week review of what happened in ophthalmology from April 9-April 15.

This affordable device allows the view through a slit lamp to be shared in real time or recorded, for teaching purposes and for reference.

A large retrospective analysis was carried out to investigate various risk factors for endophthalmitis as well as the effect of using a hydrogel sealant.

Approval is based on year 1 data from the Phase III KESTREL and KITE trials investigating brolucizumab 6 mg versus aflibercept 2 mg in DMO patients.

Developments in imaging, translational research and clinical trials of treatments for retinal diseases dominated discussion at the two-day Bascom Palmer Eye Institute Angiogenesis, Exudation, and Degeneration 2022 virtual conference.

Lower dose of bevacizumab is as effective as a higher dose for treating retinopathy of prematurity.

Dr Taiichi Hikichi counteracted the potential inflammatory effect of brolucizumab by combining its administration with a sub-Tenon’s capsule injection of triamcinolone acetonide.

The company’s announcement marks first clinical trial in humans of Ocugen’s modifier gene therapy platform.

A team of investigators at the Okinawa Institute of Science and Technology Graduate University in Japan have identified a gene necessary for the survival of retinal ganglion cells—a class of neurons located in the retina that are critical for vision.

Investigators find that fusing human retinal cells with adult stem cells could be a potential therapeutic strategy to treat retinal damage and visual impairment.

Sub-retinal injection of adeno-associated virus leads to visual acuity gains.

Ultrasonic retinal prosthesis has been achieved by a research group at UCLA. It is a step towards a non-invasive retinal prosthesis that works without invasive eye surgery.

Retinal changes seen in suspected transient ischaemic attacks are not helpful for predicting ischaemic events.

Dr Aleksandra Rachitskaya discusses how the treatment landscape for Inherited Retinal Diseases has changed and her hope for the future.

Alimera Sciences, Inc. announces statistically significant improvements in best corrected visual acuity, central subfield thickness and treatment burden for patients with diabetic macular oedema.

Dr Quan Dong Nguyen reviews a Monte Carlo simulation that showed evidence that treating severe NPDR with anti-VEGF therapy garners positive results.

Researchers know that parts of the retina are considered as biomarkers for Alzheimer disease, but the team from Otago’s Dunedin Multidisciplinary Health and Development Research Unit in New Zealand have been investigating the retina’s potential to indicate cognitive change earlier in life.

Kriya Therapeutics company recently took the wraps off an exclusive agreement with the Medical University of South Carolina (MUSC) Foundation for Research Development to license next generation complement-targeted gene therapies for the treatment of geographic atrophy and other ocular diseases.

Novel treatment reduces treatment burden and improves outcomes.

At Angiogenesis, Dr David Brown presented the Phase 2 results of the CANDELA study for high dose aflibercept 8 milligram for wet AMD; here, he discusses those results.

A brief overview of findings presented at the 2022 Angiogenesis, Exudation and Degeneration meeting hosted by Bascom Palmer.

Investigators in the Netherlands have developed an RNA therapy to halt the progression of Stargardt disease.

Dr Carel Hoyng divulges the main takeaways from his Angiogenesis presentation, including the origins of Stargardt disease, correct diagnosis, ongoing gene therapy trials and the future of therapy.

Dr Carl Regillo discusses the 100-week results of KESTREL and KITE, two pivotal Phase 3 studies for brolucizumab for the treatment of diabetic macular oedema.